Shanghai Longwood Biopharmaceuticals Co., Ltd.
Clinical trials sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hepatitis b drug enters human trials – could it help control the virus? Results expected Mar 2027 (estimated)
-
New eczema drug shows promise in Mid-Stage trial
Disease control CompletedThis study tested an experimental drug called LW402 in 144 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, thickness, and itching. Participants received either the drug or a placebo, and doctors measured skin impro…
Phase 2 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New oral drug shows promise in early arthritis trial
Disease control CompletedThis study tested a new oral medication called LW402 in 72 adults with moderate to severe rheumatoid arthritis who were already taking methotrexate. Participants received either LW402 or a placebo for 12 weeks to see if the drug could reduce joint swelling and pain. The goal was …
Phase 2 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug LW402 takes first step: safety check in 36 volunteers
Knowledge-focused CompletedThis early-stage trial tested the safety and tolerability of LW402 tablets in 36 healthy volunteers. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moves through the body. Since this is a Phase 1 study, the main goa…
Phase 1 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC